Berenberg raises Burckhardt Compression price target on record sales

Berenberg raised its price target on Burckhardt Compression (SIX:BCHN:SW) to CHF800 from CHF753, maintaining a Buy rating after the company reported record fiscal year sales of CHF1.096 billion, a 13% year-over-year increase exceeding estimates. The company's EBIT margin improved to 12.9%, with a book-to-bill ratio of 1.05x, and it announced a dividend of CHF18 per share; however, guidance for fiscal year 2025 projects minimal sales growth at CHF1.1 billion with stable EBIT margins.

Analysis

Berenberg has increased its price target for Burckhardt Compression Holding AG (SIX:BCHN:SW) to CHF800.00 from CHF753.00, reaffirming a Buy rating, subsequent to the company's robust fiscal year results ending March 2025. Burckhardt Compression reported record sales surpassing CHF1 billion for the first time, reaching CHF1,096 million, a 13% year-over-year increase that exceeded both Berenberg and consensus estimates by 2-3%. This strong top-line performance was accompanied by a significant improvement in profitability, with the EBIT margin expanding to 12.9% from 11.7% in the prior year, beating analyst expectations by 5-7%. A book-to-bill ratio of 1.05x underscores continued demand momentum and provides visibility for future revenue. The company also announced a dividend of CHF18 per share, slightly ahead of Berenberg's forecast. However, for fiscal year 2025, Burckhardt Compression's guidance of CHF1.1 billion in sales suggests minimal growth from the record levels just achieved, with an expectation for EBIT margins to remain stable. This conservative outlook, despite the current strong positive sentiment reflected in a signal score of 0.85, indicates a potential stabilization phase after a period of significant growth.

Key Decisions for Investors

• Investors should acknowledge the strong financial performance exhibited in the record fiscal year 2025 results and the positive analyst sentiment underscored by Berenberg's price target increase and maintained Buy rating.
• The company's guidance for minimal sales growth in fiscal year 2025, projecting CHF1.1 billion, alongside stable EBIT margins, warrants careful monitoring as it may suggest a slowdown from the recent high growth trajectory, despite a healthy 1.05x book-to-bill ratio indicating ongoing demand.
• The increased dividend payment to CHF18 per share, exceeding analyst expectations, signals management's confidence and could be an attractive consideration for income-focused investors, though the flat forward guidance should temper overall growth expectations.